Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Aftertreated polymer
Patent
1998-01-26
2000-08-29
Kulkosky, Peter F.
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Aftertreated polymer
514906, 424 7817, C08K 522, A01N 3326
Patent
active
061104531
ABSTRACT:
A polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.
REFERENCES:
patent: 3153094 (1964-10-01), Reilly
patent: 4265714 (1981-05-01), Nolan et al.
patent: 4298595 (1981-11-01), Pakinson et al.
patent: 4460560 (1984-07-01), Tokes et al.
patent: 4482533 (1984-11-01), Keith
patent: 4638079 (1987-01-01), Inskip et al.
patent: 4659553 (1987-04-01), Urquhart et al.
patent: 4708854 (1987-11-01), Grinstead
patent: 4877606 (1989-10-01), Churchill et al.
patent: 4888413 (1989-12-01), Domb
patent: 4921683 (1990-05-01), Bedell
patent: 4952289 (1990-08-01), Ciccone et al.
patent: 4954526 (1990-09-01), Keefer
patent: 4985471 (1991-01-01), Ohta et al.
patent: 5039705 (1991-08-01), Keefer et al.
patent: 5087631 (1992-02-01), Shaffer et al.
patent: 5087671 (1992-02-01), Loeppky et al.
patent: 5094815 (1992-03-01), Conboy et al.
patent: 5402919 (1995-04-01), Keefer et al.
patent: 5718892 (1998-02-01), Keefer et al.
Artysbasheva et al., "Synthesis of 1-Alkoxy-3,3-Dialkyltriazene 2-Oxides from Alkoxyamines an Nitrosoamines," translated from Zhurnal Organicheskoi Khimii (Journal of Organic Chemistry--U.S.S.R.), 28(6) 1168-1173 (1987).
Bonakdar et al., "Continuous-Flow Performance of Carbon Electrodes Modified with Immobilize Fe(II)/FE(III) Centers," Calanta, 36 No. 1/2, 219-225 (1999).
DeFeudis, Endothelium-Dependent Vasorelaxation--A New Basis for Developing Cardiovascular Drugs Drugs of Today, 24(2), 103-115 (1988).
DeLuca et al., Parenteral Drug-Delivery Systems, Pharmaceutics and Pharmacy Practice, (1982).
Drago et al., "The Reaction of Nitrogen (II) Oxide with Various Primary and Secondary Amines," Journal of Amer. Chem. Soc., 83, (1961).
Drago, "Reactions of Nitrogen (II) Oxide." Advances in Chemistry Series. No. 36, (1962).
Furchgott, The Role of Endothelium in the Responses of Vascular Smooth Muscle to Drugs, Ann. Rev., Pharmacol. Toxicol., 24, 175-197 (1984).
Garg et al., Nitric Oxide-Generating Vasodilators Inhibit Mitogenesis and Proliferation of Balb/C3T Fibroblasts by a Cyclic GMP-Independent Mechanism, Biochem. And Biophys. Res. Comm., 171, 474-47 (1990).
Hansen et al., "N-Nitrosation of Secondary Amines by Nitric Oxide Via the `Drago Complex`," AIRC Sci. Publ. No. 41, 21-29 (1982).
Hibbs, Jr. et al., "Nitric Oxide: A Cytotoxic Activated Macrophage Effector Molecule," Biochem. And Biophys. Res. Comm., 157, 87-94 (1988).
Holford et al., "Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic Pharmacodynamic Models," Clinical Pharmacokinetics, 6, 429-453 (1981).
Ignarro et al., "Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside and Nitric Oxide: Evidence for the Involvement of S-Nitrosothiols as Active Intermediates," J. Pharmacol. Exp. Ther., 218, 739-749 (1981).
Ignarro et al., "The Pharmacological and Physiological Role of Cyclic GMP in Vascular Smooth Muscle Relaxation," Annu. Rev. Pharmacol. Toxicol., 25, 171-191 (1985).
Ignarro, Nitric Oxide. A Novel Signal Transduction Mechanism for Transcellular Communication, Hypertension (Dallas), 16, 477-483 (1990).
Ignarro, "Biosynthesis and Metabolism of Endothelium-Derived Nitric Oxide," Annu. Rev. Pharmacol. Toxicol., 30, 535-560 (1990).
Ignarro, "Endothelium-Derived Nitric Oxide: Actions and Properties," The FASEB Journal, 3, (1989).
Jones, "Metastable Polymers of the Nitrogen Oxides. 1. Open Chain Nitric Oxide Analogues of Polythlazyl: MNDO/AM1 Study," J. Phys. Chem., 95, 2588-2595 (1991).
Kruszyna et al., Red Blood Cells Generate Nitric Oxide from Directly Acting, Nitrogenous Vasodilators, Toxicol. Appl. Pharmacol., 91, 429-438 (1987).
Kuhn et al., "Endothelium-Dependent Vasodilatation in Human Epicardial Coronary Epicardial Coronary Arteries: Effect of Prolonged Exposure to Glycerol Trinitrate or SIN-1," J. Cardiovasc. Pharmacol., 14, (Suppl. 11), s47-s5 (1989).
Longhi et al., "Metal-Containing Compounds of the Anion (C.sub.2 H.sub.6).sub.2 NN.sub.2 O.sub.2-," Insrg. Chem., 2, Feb. (1963).
Lutz et al., "Isolation of Trioxodinitrato (II) Complexes of Some First Row Transition Metal Ions," J.C.S. Chem. Commun., (1977).
Maragos et al., "Complexes of NO with Nucleophiles as Agents for Controlled Biological Release of Nitric Oxide. Vasorelaxant Effects," J. Med. Chem., 34, 3242-3247 (1991).
Marletta et al., "Unraveling the Biological Significance of Nitric Oxide," BioFactors, 2, 219-225 (1990).
Middleton et al., "Further Studies on the Interaction of Nitric Oxide with Transition-Metal Alkyls," J.C.S. Dalton, 1898-1905 (1981).
Myers et al., "Vasorelaxant Properties of the Endothelium-Derived Factor more closely Resemble S Nitrosocystein Than Nitric Oxide," Nature, 345, (1990).
Nakanishi et al., Participation of Hydrocarbons in the Photodimerization of 3, 4-Dichlorocinnamic Acid, J.C.S. Chem. Comm., (1977).
Palmer et al., "Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor," Nature, 327(11), (1987).
Park et al., "Controlled Protein Release from Polyethyleneimine-Coated Poly (L-lactic Acid)/Plurunic Blen Matrices," Pharmaceutical Research, 9(1), (1992).
Smith et al., "Complex Contractile Patterns in Canine Colon Produced by Spontaneous Release of Nitric Oxide," Gastroenterology, 102(4) Part 2, (1992).
Smith et al., "Nitroprusside: A Potpourri of Biologically Reactive Intermediates," Biological Reactive Intermediates IV. Molecular and Cellular Effects and Their Impact on Human Health, (Witmer et al., eds.) Advances in Experimental Medicine and Biology, vol. 283, (Plenum Press), 365-369 (1991).
Stampler et al., "S-Nitrosylation of Proteins with Nitric Oxide: Synthesis and Characterization of Biologically Active Compounds," Proc. Natl. Acad. Sci., USA, 89, 444-448 (1992).
Stuehr et al., "Nitric Oxide: A Macrophage Product Responsible for Cytostasis and Respiratory Inhibition in Tumor Target Cells," J. Exp. Med., 169, 1543-1555 (1989).
Trissel, Intravenous Infusion Solutions, Handbook on Injectable Drugs, Fourteenth Edition (1986).
WHO Task Group on Environmental Health Criteria for Oxides of Nitrogen, Oxides of Nitrogen Environmental Health Criteria 4 (World Health Organization: Geneva) (1977).
Wilcox et al., "Effect of Cyanide on the Reaction of Nitroprusside with Hemoglobin: Relevance to Cyanid Interference with the Biological Activity of Nitroprusside," Chem. Res. Toxicol., 3, 71-76 (1990).
Uber Reaktionen und Eigenschaften des Stickoxyds und seiner Verbindungen, II. Mitteil: Zur Kenntnis de Salze Der stickoxyd-schwefligen Saure, Heinz Gehlen, Aug. D. Chem. Instit D. Universtat Konigsberg I PR., Eingegaugen am 1. Jun. (1932).
Der Raman-Effekt als Grundlage einer organischen Spektralanalyse (I. Mitteil.), Birchkenbach, et al., Aus D. Chem. Institut D. Betgakademie Clausthal, Eingegaugen am 9, Jun. (1932).
Weitz et al., "Zur Kenntnis der stickoxyd-schwefligen Saure (II. Mitteil)," Berichte d. D. Chem. Gesellschaft LXVI, 1718-1727 (1993). ("Nitrosylsulfuric acid," Chemical Abstracts, 28, 2636).
Chemical Abstracts, 100:68900, 105:210200 (1986).
Chemical Abstracts, 72:69179.
Hrabie Joseph A.
Keefer Larry K.
ICN Pharmaceuticals, Inc.
Kulkosky Peter F.
The United States of America as represented by the Department of
LandOfFree
Polymer-bound nitric oxide/nucleophile adduct compositions, phar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymer-bound nitric oxide/nucleophile adduct compositions, phar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymer-bound nitric oxide/nucleophile adduct compositions, phar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1246635